HOW CAN WE STOP EARLY PRE-CANCER LESIONS BY DETERMINING THE RELATIVE RISK AT THE INDIVIDUAL LEVEL?

Your idea for addressing this Cancer Interception challenge could be a strategy for developing diagnostic test and associated surrogate endpoints that would serve to:

a) Identify those individuals with premalignancies who are most likely to progress.
b) Accurately measure the clinical response of those individuals with high cancer risk, who will receive treatment.